References
- Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study ofsorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300 https://doi.org/10.1200/JCO.2005.01.3441
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advancedhepatocellular carcinoma. N Engl J Med 2008;359:378-390 https://doi.org/10.1056/NEJMoa0708857
- Llovet JM, Bruix J. Systematic review of randomized trialsfor unresectable hepatocellular carcinoma: chemoembolizationimproves survival. Hepatology 2003;37:429-442 https://doi.org/10.1053/jhep.2003.50047
- Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updatedanalysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-1547 https://doi.org/10.1111/j.1365-2036.2006.02932.x
- Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibitsbroad spectrum oral antitumor activity and targets theRAF/MEK/ERK pathway and receptor tyrosine kinases involvedin tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109 https://doi.org/10.1158/0008-5472.CAN-04-1443
- Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY43-9006) inhibits tumor growth and vascularization and inducestumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-574 https://doi.org/10.1007/s00280-006-0393-4
- Philip PA, Mahoney MR, Allmer C, et al. Phase II study ofErlotinib (OSI-774) in patients with advanced hepatocellularcancer. J Clin Oncol 2005;23:6657-6663 https://doi.org/10.1200/JCO.2005.14.696
- Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study ofgemcitabine and oxaliplatin in combination with bevacizumabin patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-1903 https://doi.org/10.1200/JCO.2005.04.9130